Drug Topics
DECEMBER 4, 2023
An evaluative study on an open resource Instagram page that provides information on new medications to pharmacists was recently presented at the American Society of Health-System Pharmacists 2023 Midyear Clinical Meeting and Exhibition.
Pharmacy Times
DECEMBER 4, 2023
Three classes of drugs could be 2 to 5 times more effective than ibuprofen for the treatment of migraine attacks, according to results of a study.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 4, 2023
The Senate health care committee will consider a sweeping bill next week meant to combat the opioid epidemic, according to four lobbyists and a congressional aide familiar with the legislation. The proposal would reauthorize a number of programs first created by the SUPPORT Act, an addiction-focused bill that Congress first passed in 2018. Many of those programs’ authorizations expired earlier this year, however, leading addiction treatment advocates to fret that lawmakers —
Pharmacy Times
DECEMBER 4, 2023
The study authors note that additional policies to reduce structural stigma against sexual minorities could continue to improve the rate of individuals who initiate PrEP use.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
DECEMBER 4, 2023
Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes. The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary.
Drug Topics
DECEMBER 4, 2023
A poster from ASHP Midyear 2023 demonstrated the effectiveness of liposomal bupivacaine as it is used for cesarean section procedures, regarded as an area with increasing utilization.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
DECEMBER 4, 2023
In this conversation from HAS 2023, Randy Falkenrath demystifies the oncology medication management model and explains how specialty pharmacist can help patients access care.
STAT
DECEMBER 4, 2023
WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday. The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September.
Pharmacy Times
DECEMBER 4, 2023
Pirtobrutinib is the first and only non-covalent BTK inhibitor to be approved by the FDA and is indicated for adult patients who already received at least 2 prior lines of therapy.
STAT
DECEMBER 4, 2023
The medical community today faces a deceptively simple question: How quickly should we act when a child’s life is on the line? I’m a pediatric oncologist, so my answer won’t surprise you — I think we should act immediately. But a new Food and Drug Administration policy could delay things for children who need treatment now.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
DECEMBER 4, 2023
The proportion of prescriptions by a 340B-affiliated physician increased from 9.4% in 2013 to 19.3% in 2020, but the prescriptions filled by 340B pharmacies increased from 18.4% to 49.9%.
Fierce Healthcare
DECEMBER 4, 2023
Five years ago, Liya Shuster-Bier entered cancer as an otherwise healthy 29-year-old. | Maia Oncology raised $4.25 million in seed funding to hone its go-to-market strategy, hire more talent and launch its first pilot in partnership with a cancer center and health insurance company.
Drug Topics
DECEMBER 4, 2023
According to a poster presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition, stress ulcer prophylaxis (SUP) did not increase adverse effects, suggesting limited preventive benefits for gastrointestinal bleeding (GIB) in neonates.
Fierce Healthcare
DECEMBER 4, 2023
Northwell Health has teamed up with New York City organizations to launch a new pilot program that aims to improve healthcare services for young adults transitioning out of foster care. | Working with the Administration for Children's Services and the Center for Fair Futures’ coaches, the program will enroll 50 to 100 transition-age adults, pairing them with Northwell’s patient navigation services.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
DECEMBER 4, 2023
Fujifilm Corporation is spreading the wealth across two production units as the contract development and manufacturing organization (CDMO) juggernaut works through a cell therapy expansion. | Fujifilm is dividing $200 million between a pair of subsidiaries. Those are: Fujifilm Cellular Dynamics, which specializes in development and manufacturing of human induced pluripotent stem cells (iPSC), and the organization’s CDMO for biologics and advanced therapies, Fujifilm Diosynth Biotechnologies.
pharmaphorum
DECEMBER 4, 2023
Roche has agreed a deal to acquire US biotech Carmot Therapeutics that if consummated will thrust it into the increasingly competitive market for incretin-based therapies for diabetes and obesity. The Swiss pharma group has agreed to pay $2.7 billion upfront in cash when the deal closes, with shareholders in the US company also in line for up to $400 million if the drug programmes covered by the agreement meet various milestones.
Fierce Pharma
DECEMBER 4, 2023
A challenging year for the biotech industry has taken a heavy toll on Chinese manufacturer WuXi Biologics, sending the company’s stock plummeting nearly 24% Monday. | WuXi Biologics expects to miss its original sales target for the year by around $400 million, thanks to reductions across its development and manufacturing services. WuXi blamed the projected miss largely on a COVID-related revenue slowdown and a decline in projects.
Drug Topics
DECEMBER 4, 2023
Three poster presented at the ASHP Midyear Clinical Meeting delved deeper into perioperative pain management.
STAT
DECEMBER 4, 2023
Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. How sickle cell became the first CRISPR’d disease Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes.
Pharmacy Times
DECEMBER 4, 2023
Despite nearly one-third of reversible dementia cases being drug induced, cognitive safety is a neglected aspect of clinical trials.
Drug Store News
DECEMBER 4, 2023
Listen to DSN's "Capturing the Modern Male Shopper" webinar, which includes insights from Spotify, Reddit and Hawthorne to examine the next big trends, deep dive on marketing crossovers and more.
Fierce Healthcare
DECEMBER 4, 2023
The Joint Commission is launching a voluntary certification program for hospitals and critical access hospitals to demonstrate their responsible use of patient’s health data for non-clinical purpos | The accreditation giant wants its Responsible Use of Health Data Certification program to serve as an objective evaluation of whether a hospital is following best practices around secondary use of data.
Pharmacy Times
DECEMBER 4, 2023
A new hydrogel drug delivery system could change the way diabetes is managed.
Fierce Healthcare
DECEMBER 4, 2023
Data on Blue Shield of California members may have been exposed due to a vulnerability in the MOVEit file transfer platform. | Data on Blue Shield of California members may have been exposed due to a vulnerability in the MOVEit file transfer platform.
Pharmacy Times
DECEMBER 4, 2023
Although personality was linked to cognitive performance on tests, it was not linked to dementia pathophysiology.
STAT
DECEMBER 4, 2023
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so familiar routine of online meetings, phone calls, and deadlines has predictably returned. But you knew this would happen, yes? After all, the world, such as it is, somehow keeps spinning. So time to nudge it in a better direction with a fresh cup of stimulation.
The Checkup by Singlecare
DECEMBER 4, 2023
Coming off the COVID-19 pandemic, 2023 was a much more normal year of health news. Jimmy Kimmel made jokes about Ozempic at the Oscars, artificial intelligence (AI) saw its early implementation in healthcare, and researchers made sweeping innovations in the treatment of harmful diseases. It was a year of innovation, but also a year of prescription drug shortages and price hikes.
The Guardian - Pharmaceutical Industry
DECEMBER 4, 2023
Modern medicine makes it seem as if drugs are the only way to deal with diabetes. But what if diet can be a solution? One gray Sunday in the middle of the Covid lockdown, I received an unwelcome call from my family doctor. Until then, for virtually my entire life, I had managed to stay out of a doctor’s office, except for routine checkups. My luck had run out.
The Checkup by Singlecare
DECEMBER 4, 2023
You may have heard about SingleCare from your pharmacist or through a television commercial. It’s likely you know that SingleCare can help you save up to 80% on prescription costs—but you may not know all about the free prescription savings card. For instance, did you know you can use our card even if you have insurance, Medicaid, or Medicare? It’s true!
Fierce Healthcare
DECEMBER 4, 2023
New Jersey’s largest academic medical center has reached a tentative agreement with a union representing about 1,700 of its nurses to end a four-month strike. | The labor dispute over pay and staffing held about 1,700 nurses without pay or benefits and drew the attention of top U.S. health policy legislators.
STAT
DECEMBER 4, 2023
WASHINGTON — The Supreme Court on Monday wrestled with a nationwide settlement with OxyContin maker Purdue Pharma that would shield members of the Sackler family who own the company from civil lawsuits over the toll of opioids. The justices seemed by turns relucant to break up an exhaustively negotiated agreement, but also leery of somehow rewarding the Sacklers.
Fierce Healthcare
DECEMBER 4, 2023
After spending nearly $20 billion to pick up Signify Health and Oak Street Health this year, CVS rebranded its health services business to "CVS Healthspire" as it plots its long-term growth strateg | After spending nearly $20 billion to pick up Signify Health and Oak Street Health this year, CVS rebranded its health services business to "CVS Healthspire" as it plots its long-term growth strategy.
STAT
DECEMBER 4, 2023
In the wake of the Covid-19 pandemic, the Food and Drug Administration inspected far fewer domestic and foreign pharmaceutical facilities, even though manufacturing activity did not decline, according to a new analysis. Meanwhile, FDA budgeting and staffing held steady, although resources allocated for each inspection surged and more plants were cited for serious violations.
European Pharmaceutical Review
DECEMBER 4, 2023
The European Commission (EC ) has authorised ZILBRYSQ ® (zilucoplan)▼ as the first once-daily subcutaneous (SC), targeted peptide inhibitor of complement component 5 (C5) inhibitor for generalised myasthenia gravis ( gMG ). It is also the only C5 inhibitor approved for self-administration by adult patients who are AChR antibody-positive with this disease.
Expert insights. Personalized for you.
211 
Let's personalize your content